Hematopoietic Growth Factors Version 1.2020 Featured Updates to the NCCN Guidelines
Hematopoietic Growth Factors Version 1.2020 Featured Updates to the NCCN Guidelines
复制标题
DOI：
10.6004/jnccn.2020.0002
复制
发表时间：
2020-01-01
影响因子：
13.4
通讯作者：
Pluchino, Lenora A.
中科院分区：
文献类型：
--
作者：
Becker, Pamela Sue;Griffiths, Elizabeth A.;Pluchino, Lenora A.
发热性中性粒细胞减少症（FN）的管理是接受癌症治疗的患者支持性护理的一个组成部分。NCCN造血生长因子指南为FN的适当评估、风险确定、预防和管理提供了建议。这些NCCN指南旨在指导临床医生在接受非髓系恶性肿瘤治疗的患者中适当使用生长因子。这些NCCN指南见解强调了NCCN指南关于纳入fda新批准的用于FN预防和治疗的粒细胞集落刺激因子生物类似药的重要更新。
Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.